WallStSmart
ZBIO

Zenas BioPharma, Inc. Common Stock

NASDAQ: ZBIO · HEALTHCARE · BIOTECHNOLOGY

$20.40
-4.95% today

Updated 2026-06-05

Market cap
$1.16B
P/E ratio
P/S ratio
119.50x
EPS (TTM)
$-9.10
Dividend yield
52W range
$9 – $45
Volume
0.7M

Zenas BioPharma, Inc. Common Stock (ZBIO) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2022202320242025
Revenue$0.00$50.00M$5.00M$10.00M
Revenue growth (YoY)-90.0%+100.0%
Cost of revenue$61.69M$113000.00$139.14M$56000.00
Gross profit$-61.69M$50.00M$-134.14M$10.00M
Gross margin100.0%-2682.8%100.0%
R&D$62.69M$60.03M$139.14M$168.06M
SG&A$12.81M$17.11M$28.85M$53.32M
Operating income$-76.20M$-37.15M$-163.89M$-211.38M
Operating margin-74.3%-3277.8%-2113.8%
EBITDA$-75.12M$-27.03M$-163.75M$-370.43M
EBITDA margin-54.1%-3275.0%-3704.3%
EBIT$-75.20M$-27.15M$-163.89M$-370.49M
Interest expense$0.00$7.33M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%
Net income$-119.28M$-37.12M$-156.99M$-377.74M
Net income growth (YoY)+68.9%-322.9%-140.6%
Profit margin-74.2%-3139.8%-3777.4%

Frequently asked questions

How profitable is ZBIO?

In its most recent fiscal year, ZBIO ran a gross margin of 100.00%, an operating margin of -2,113.85%, and a net margin of -3,777.37%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does ZBIO generate?

ZBIO produced $-172.35M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ZBIO's balance sheet healthy?

ZBIO holds $110.64M in cash and equivalents against — in long-term debt, on $242.14M of shareholder equity. That debt is best read against the cash flow the business throws off each year.